ArticleFrontiers in oncology2026
Hepatic carcinosarcoma: a rare and aggressive case with unusual molecular signature!
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary hepatic carcinosarcoma is a rare, aggressive tumour with both carcinomatous and sarcomatous components. Limited documented cases hinder comprehensive understanding, making diagnosis, treatment, and management particularly challenging for clinicians. Case: A 62-year-old female, with prior cervical squamous cell carcinoma 7 years ago, underwent right hemihepatectomy, cholecystectomy, and diaphragmatic resection in 2025. Grossly, a 180 mm white hepatic tumour with a large cystic cavity was seen adherent to the diaphragm, extending to the resection margin (R2), while the hepatic resection margin was clear (R0). Histology confirmed hepatic carcinosarcoma (pT4), comprising cholangiocarcinoma (CK7, BerEP4+), hepatocellular carcinoma (Glypican-3+), and squamous carcinoma (p63, p40+). Sarcomatous areas included rhabdomyosarcomatous (Desmin, Myogenin, MyoD1+), leiomyosarcomatous (SMA+), and chondrosarcomatous (S100+) differentiation. PLAP and CD117 positivity suggested germ cell-like features. There is no distinct separation between the carcinomatous and sarcomatous components. Molecular profiling revealed a KIAA1549::BRAF fusion alongside oncogenic variants: TERT c.-124C>T (VAF 0.60) and TP53 c.811G>A p. (Glu271Lys) (VAF 0.90). Targeted panel sequencing showed no other actionable mutations. MSI readout was 2.5%, confirming microsatellite stability (MSS). Outcome: Multidisciplinary review at tertiary centres confirmed the rarity and grave outlook. The patient developed early recurrence with thoraco-abdominal deposits, venous thromboembolism, and pleural effusion. Paclitaxel-carboplatin chemotherapy was commenced with dose modifications for hepatotoxicity, complicated by infusion reactions, mild neuropathy, and mucositis. Conclusion: This case underlines the extreme morphological and molecular heterogeneity of hepatic carcinosarcomas, the rapid progression despite surgery, and the limited systemic treatment options available for such rare tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.